


Roche’s Bold Foray into Obesity Treatment: A $5.3 Billion Bet on Petrelintide
In a strategic move poised to reshape the landscape of

Brisbane Biotech Gelomics Raises $2.2 Million in Pre-Seed Funding
In a significant stride towards ethical biomedical advancements, Brisbane-based biotech

UroGen Aims to Raise $107M to Advance Innovative Obesity and Bladder Cancer Therapies
Introduction Overview of UroGen: UroGen Pharma Ltd., headquartered in Princeton,
